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During the past 15 years, monoclonal anti-
bodies (mAbs) have become an important 
tool for the treatment of hematopoietic 
and solid malignancies. The mAbs that 
have been approved by regulatory agencies 
for use in cancer patients as well as those 
that are currently being developed in this 
sense target antigens that are overexpressed 
on the surface of cancer cells and mediate 
antineoplastic effects via multiple, often 
non-mutually exclusive, mechanisms.1–3 
Thus, while trastuzumab (Herceptin™, 
Roche) mainly (but not only) inhibits 
the signal transduction cascade elicited 
by the v-erb-b2 erythroblastic leukemia 
viral oncogene homolog 2 (ERBB2, best 
known as HER2), rituximab (Rituxan™, 
Genentech) exerts antitumor effects 
mostly by engaging the host immune sys-
tem against CD20-expressing cancer cells, 
hence activating both antibody-dependent 
and complement-dependent cellular cyto-
toxicity.4,5 These mAbs are often used in 
combination with radio- and/or chemo-
therapeutic regimens, and are generally 
associated with relatively mild and tran-
sient side effects.3,6
Along with the development of mAbs 
that would exert antineoplastic effects as 
such, i.e., “naked” mAbs, the therapeu-
tic potential of mAbs that specifically 
shuttle cytotoxic agents or radioisotopes 
to malignant cells, hence minimizing 
unwarranted toxic phenomena, has been 
intensively investigated. The efficacy 
of these “immune conjugates” largely 
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relies on their internalization by cancer 
cells via receptor-mediated endocytosis, 
resulting in the highly specific delivery 
of their cytotoxic moiety.7 Nowadays, no 
less than 3 distinct immune conjugates 
are approved by the US Food and Drug 
Administration (FDA) for use in can-
cer patients,1,2 including ibritumomab 
tiuxetan (Zevalin™, IDEC pharma-
ceuticals), an 90Y- or 111In-conjugated 
murine IgG1 targeting CD20 that is 
currently employed for the treatment of 
relapsed or refractory, low grade or fol-
licular B-cell non-Hodgkin’s lymphoma 
(NHL);8 tositumomab (Bexxar™, 
GlaxoSmithKline), an 131I-conjugated 
fully human IgG1 specific for CD20 that 
is being used against CD20-expressing 
relapsed or refractory, low-grade, follicular 
or transformed NHL;9 and brentuximab 
vedotin (AdcetrisTM, Seattle Genetics), 
a CD30-targeting chimeric IgG1 con-
jugated to monomethyl auristatin E 
(MMAE, an inhibitor of tubulin) that is 
approved for use in Hodgkin’s lymphoma 
patients relapsing upon autologous hema-
topoietic stem cell transplantation.10
On February 22nd, 2013, the FDA 
approved a new immune conjugate for 
the treatment of advanced breast carci-
noma, trastuzumab emtansine (T-DM1, 
commercialized by Genentech under the 
label of KadcylaTM). T-DM1 combines the 
ability of trastuzumab to inhibit ERBB2 
signaling and activate the host immune 
system with the selective delivery of the 
maytansinoid DM1, another tubulin 
inhibitor, to ERBB2+ cancer cells. Thus, 
whereas the antibody moiety of T-DM1 is 
degraded by lysosomes upon ERBB2 inter-
nalization, DM1 is released in the cyto-
plasm and exerts additional antineoplastic 
effects by halting cell cycle progression.11
The EMILIA Phase III clinical trial, 
which de facto drove the approval of 
T-DM1, enrolled a total of 991 patients 
affected by ERBB2+ advanced or metastatic 
breast carcinoma that had previously been 
treated with trastuzumab and a micro-
tubular inhibitor of the taxane family.12 
Patients were randomly assigned to receive 
either T-DM1 as a standalone intervention 
or lapatinib (an FDA-approved chemical 
inhibitor of the tyrosine kinase activity of 
ERBB2) plus capecitabine (the precursors 
of the nucleoside analog 5-fluorouracil). 
In this setting, the intravenous admin-
istration of T-DM1 every 21 days sig-
nificantly prolonged overall survival from 
25.1 months, as observed in the control 
arm of the study, to 30.9 months. Along 
similar lines, T-DM1-receiving patients 
exhibited a longer progression-free survival 
(9.6 months) than patients treated with 
lapatinib plus capecitabine (6.4 months), 
and T-DM1 was associated with a com-
paratively lower frequency of grade 3–4 
adverse events (40.8% vs. 57%). These 
included thrombocytopenia (documented 
in 12.9% of T-DM1-receiving patients) 
but not severe diarrhea or palmar-plantar 
erythrodysestesia, both of which were 
e24567-2 OncoImmunology Volume 2 Issue 6
commonly observed in subjects treated 
with lapatinib plus capecitabine.12
A recent meta-analysis of clinical data 
demonstrates that neo-adjuvant trastu-
zumab not only significantly improves 
both disease-free and overall survival 
among metastatic breast carcinoma 
patients bearing the ERBB2 amplifica-
tion, which is observed in approximately 
20% of cases and is associated with poor 
prognosis,13 but also reduces the risk of 
relapse upon surgical removal of the pri-
mary tumor.14 Thus, the clinical indica-
tions for T-DM1, which has specifically 
been approved for use in patients who 
previously failed combinatorial immu-
nochemotherapeutic regimens involv-
ing trastuzumab and a taxane, may soon 
expand.
Several other immune conjugates are 
being developed for the treatment of 
solid and hematological malignancies,1,2 
most of which combine a tubulin inhibi-
tor (e.g., MMAE) or an anthracyclin 
(e.g., doxorubicin) with mAbs target-
ing one out of several tumor-associated 
antigens.11 Safety and efficacy data from 
recent clinical trials suggest that immune 
conjugates constitute promising tool for 
anticancer immunotherapy. The design of 
molecules that—similar to T-DM1—are 
able to engage the mechanisms of action 
of naked antibodies while specifically 
delivering cytotoxic agents or radioiso-
topes to cancer cells is expected to fur-
ther increase the therapeutic potential of 
this approach. Future will tell not only if 
mAbs of this type represent a novel class 
of superior immunotherapeutic agents, 
but also whether they can be safely and 
efficiently combined with other immuno-
modulatory interventions including, but 
not limited to, immunogenic chemother-
apeutics,15 immunostimulatory mAbs16 
and Toll-like receptor agonists.17,18
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